193 related articles for article (PubMed ID: 23838036)
1. Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome.
George EM; Herzog TJ; Neugut AI; Lu YS; Burke WM; Lewin SN; Hershman DL; Wright JD
Gynecol Oncol; 2013 Oct; 131(1):42-5. PubMed ID: 23838036
[TBL] [Abstract][Full Text] [Related]
2. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis.
Rauh-Hain JA; Diver EJ; Clemmer JT; Bradford LS; Clark RM; Growdon WB; Goodman AK; Boruta DM; Schorge JO; del Carmen MG
Gynecol Oncol; 2013 Oct; 131(1):46-51. PubMed ID: 23906658
[TBL] [Abstract][Full Text] [Related]
3. Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis.
Rauh-Hain JA; Gonzalez R; Bregar AJ; Clemmer J; Hernández-Blanquisett A; Clark RM; Schorge JO; Del Carmen MG
Gynecol Oncol; 2016 Jul; 142(1):38-43. PubMed ID: 27107722
[TBL] [Abstract][Full Text] [Related]
4. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.
Peres LC; Cushing-Haugen KL; Köbel M; Harris HR; Berchuck A; Rossing MA; Schildkraut JM; Doherty JA
J Natl Cancer Inst; 2019 Jan; 111(1):60-68. PubMed ID: 29718305
[TBL] [Abstract][Full Text] [Related]
5. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
6. Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes.
Garg G; Shah JP; Kumar S; Bryant CS; Munkarah A; Morris RT
Int J Gynecol Cancer; 2010 Jul; 20(5):888-94. PubMed ID: 20606539
[TBL] [Abstract][Full Text] [Related]
7. Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior.
Bansal N; Herzog TJ; Seshan VE; Schiff PB; Burke WM; Cohen CJ; Wright JD
Obstet Gynecol; 2008 Jul; 112(1):64-70. PubMed ID: 18591309
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic characteristics and survival outcomes in neuroendocrine carcinoma of the ovary.
Zhu Y; Meng F; Fang H; Zhang Z; Wang L; Zheng W
Int J Gynecol Cancer; 2020 Feb; 30(2):207-212. PubMed ID: 31796530
[TBL] [Abstract][Full Text] [Related]
9. Survival rates for international federation of gynecology and obstetrics stage III ovarian carcinoma by cell type: a study of 262 unselected patients with uniform pathologic review.
Seidman JD; Yemelyanova A; Cosin JA; Smith A; Kurman RJ
Int J Gynecol Cancer; 2012 Mar; 22(3):367-71. PubMed ID: 22237384
[TBL] [Abstract][Full Text] [Related]
10. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome and natural history of uterine adenosarcomas.
Arend R; Bagaria M; Lewin SN; Sun X; Deutsch I; Burke WM; Herzog TJ; Wright JD
Gynecol Oncol; 2010 Nov; 119(2):305-8. PubMed ID: 20688363
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological parameters and survival of invasive epithelial ovarian cancer by histotype and disease stage.
Lan A; Yang G
Future Oncol; 2019 Jun; 15(17):2029-2039. PubMed ID: 31140868
[No Abstract] [Full Text] [Related]
13. The effect of epithelial and stromal tumor components on FIGO stages III and IV ovarian carcinosarcomas treated with primary surgery and chemotherapy.
Athavale R; Thomakos N; Godfrey K; Kew F; Cross P; de Barros Lopes A; Hatem MH; Naik R
Int J Gynecol Cancer; 2007; 17(5):1025-30. PubMed ID: 17466043
[TBL] [Abstract][Full Text] [Related]
14. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.
Berton-Rigaud D; Devouassoux-Shisheboran M; Ledermann JA; Leitao MM; Powell MA; Poveda A; Beale P; Glasspool RM; Creutzberg CL; Harter P; Kim JW; Reed NS; Ray-Coquard I
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S55-60. PubMed ID: 25341582
[TBL] [Abstract][Full Text] [Related]
15. Prognostic determinants in patients with uterine and ovarian carcinosarcoma.
Rauh-Hain JA; Shoni M; Schorge JO; Goodman A; Horowitz NS; del Carmen MG
J Reprod Med; 2013; 58(7-8):297-304. PubMed ID: 23947079
[TBL] [Abstract][Full Text] [Related]
16. Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component.
de Jong RA; Nijman HW; Wijbrandi TF; Reyners AK; Boezen HM; Hollema H
Mod Pathol; 2011 Oct; 24(10):1368-79. PubMed ID: 21572397
[TBL] [Abstract][Full Text] [Related]
17. Uterine and Ovarian Carcinosarcomas: Do They Behave Similarly?
Ureyen I; Karalok A; Cirik DA; Tasci T; Gokce ZK; Duzguner IB; Tulunay G; Turan T
J Obstet Gynaecol Can; 2017 Jul; 39(7):559-563. PubMed ID: 28625283
[TBL] [Abstract][Full Text] [Related]
18. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy.
Pacaut C; Bourmaud A; Rivoirard R; Moriceau G; Guy JB; Collard O; Bosacki C; Jacquin JP; Levy A; Chauleur C; Magné N; Merrouche Y
Am J Clin Oncol; 2015 Jun; 38(3):272-7. PubMed ID: 23751320
[TBL] [Abstract][Full Text] [Related]
19. Carcinosarcoma of the ovary: 19 years of prospective data from a single center.
Brown E; Stewart M; Rye T; Al-Nafussi A; Williams AR; Bradburn M; Smyth J; Gabra H
Cancer; 2004 May; 100(10):2148-53. PubMed ID: 15139057
[TBL] [Abstract][Full Text] [Related]
20. Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival.
Rojas C; Tian C; Powell MA; Chan JK; Bateman NW; Conrads TP; Rocconi RP; Jones NL; Shriver CD; Hamilton CA; Maxwell GL; Casablanca Y; Darcy KM
Gynecol Oncol; 2020 Apr; 157(1):67-77. PubMed ID: 32029291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
